Evaluation of interstitial protein delivery in multicellular layers model

Archives of Pharmacal Research

Volumn 35, Issue 3, 2012, Pages 531-541

  Kim, Soo Yeon ^a   Kim, Tae Hyung ^b   Choi, Jong Hoon ^c   Lee, Kang Choon ^b   Park, Ki Dong ^c   Lee, Seung Jin ^d   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Ajou University   (South Korea)

^d Ewha Womans University   (South Korea)

Author keywords

Cetuximab; Heparin Pluronic nanogels; Multicellular layers; PEGylation; Protein delivery; TRAIL

Indexed keywords

CETUXIMAB; HEPARIN; IMMUNOGLOBULIN G; NANOMATERIAL; PACLITAXEL; POLOXAMER; RIBONUCLEASE A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CULTURE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONJUGATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG PURIFICATION; DRUG STABILITY; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; GEL; HUMAN; HUMAN CELL; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PROTEIN DELIVERY; INTERSTITIUM; MOLECULAR SIZE; MULTICELLULAR LAYER; PROTEIN TRANSPORT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL MEMBRANE PERMEABILITY; COLONIC NEOPLASMS; DRUG CARRIERS; HT29 CELLS; HUMANS; IMMUNOGLOBULIN G; MICROSCOPY, FLUORESCENCE; MOLECULAR WEIGHT; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PROTEINS; RIBONUCLEASE, PANCREATIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862850433     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0317-2     Document Type: Article

References (49)

1. Adams, G. P., Schier, R., Mccall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., and Weiner, L. M., High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res., 61, 4750-4755 (2001).
2. Al-Abd, A. M., Lee, J. H., Kim, S. Y., Kun, N., and Kuh, H. J., Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci., 99, 423-431 (2008).
3. Baker, J. H., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J. T., and Minchinton, A. I., Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin. Cancer Res., 14, 2171-2179 (2008).
4. Beckman, R. A., Weiner, L. M., and Davis, H. M., Antibody constructs in cancer therapy. Cancer, 109, 170-179 (2007).
5. Bellail, A. C., Qi, L., Mulligan, P., Chhabra, V., and Hao, C., TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. Rev. Recent Clin. Trials, 4, 34-41 (2009).
6. Calaycay, J., Pande, H., Lee, T., Borsi, L., Siri, A., Shively, J. E., and Zardi, L., Primary structure of a DNA- and heparinbinding domain (Domain III) in human plasma fibronectin. J. Biol. Chem., 260, 12136-12141 (1985).
7. Capila, I. and Linhardt, R. J., Heparin-protein interactions. Angew. Chem. Int. Ed. Engl., 41, 391-412 (2002).
8. Chae, S. Y., Kim, T. H., Park, K., Jin, C. H., Son, S., Lee, S., Youn, Y. S., Kim, K., Jo, D. G., Kwon, I. C., Chen, X., and Lee, K. C., Improved antitumor activity and tumor targeting of NH2-terminal-specific PEGylated tumor necrosis factorrelated apoptosis-inducing ligand. Mol. Cancer Ther., 9, 1719-1729 (2010).
9. Choi, J. H., Jang, J. Y., Joung, Y. K., Kwon, M. H., and Park, K. D., Intracellular delivery and anti-cancer effect of selfassembled heparin-Pluronic nanogels with RNase A. J. Control. Release, 147, 420-427 (2010).
10. Delbaldo, C., Pierga, J., Dieras, V., Faivre, S., Laurence, V., Vedovato, J., Bonnay, M., Mueser, M., Nolting, A., and Kovar, A., Pharmacokinetic profile of cetuximab (ErbituxTM) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer, 41, 1739-1745 (2005).
11. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., and Chilkoti, A., Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 98, 335-344 (2006).
12. Fujimori, K., Covell, D. G., Fletcher, J. E., and Weinstein, J. N., A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J. Nucl. Med., 31, 1191-1198 (1990).
13. Go, D. H., Joung, Y. K., Lee, S. Y., Lee, M. C., and Park, K. D., Tetronic-oligolactide-heparin hydrogel as a multi-functional scaffold for tissue regeneration. Macromol. Biosci., 8, 1152-1160 (2008).
14. Hao, Y. L., Deng, Y. J., Chen, Y., Wang, X. M., Zhong, H. J., and Suo, X. B., In vitro and in vivo studies of different liposomes containing topotecan. Arch. Pharm. Res., 28, 626-635 (2005).
15. Holden, S. A., Lan, Y., Pardo, A. M., Wesolowski, J. S., and Gillies, S. D., Augmentation of antitumor activity of an antibody- interleukin 2 immunocytokine with chemotherapeutic agents. Clin. Cancer Res., 7, 2862-2869 (2001).
16. Huxham, L. A., Kyle, A. H., Baker, J. H., Nykilchuk, L. K., and Minchinton, A. I., Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res., 64, 6537-6541 (2004).
17. Jang, S. H., Wientjes, M. G., and Au, J. L., Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J. Pharmacol. Exp. Ther., 296, 1035-1042 (2001).
18. Jang, S. H., Wientjes, M. G., Lu, D., and Au, J. L., Drug delivery and transport to solid tumors. Pharm. Res., 20, 1337-1350 (2003).
19. Johnstone, R. W., Frew, A. J., and Smyth, M. J., The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 8, 782-798 (2008).
20. Kemp, M. M. and Linhardt, R. J., Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2, 77-87 (2010).
21. Kim, M. H., Billiar, T. R., and Seol, D. W., The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem. Biophys. Res. Commun., 321, 930-935 (2004).
22. Kruyt, F. A., TRAIL and cancer therapy. Cancer Lett., 263, 14-25 (2008).
23. Kuh, H. J., Jang, S. H., Wientjes, M. G., Weaver, J. R., and Au, J. L., Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther., 290, 871-880 (1999).
24. Kyle, A. H., Huxham, L. A., Yeoman, D. M., and Minchinton, A. I., Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin. Cancer Res., 13, 2804-2810 (2007).
25. Lee, S.-I., Nagayya-Sriraman, S.-K., Shanmugam, S., Baskaran, R., Yong, C.-S., Yoon, S.-K., Choi, H.-G., and Yoo, B.-K., Effect of charge carrier lipid on skin penetration, retention, and hair growth of topically applied finasteridecontaining liposomes. Biomol Ther, 19, 231-236 (2011).
26. Liao, Y. H., Jones, S. A., Forbes, B., Martin, G. P., and Brown, M. B., Hyaluronan: Pharmaceutical characterization and drug delivery. Drug Deliv., 12, 327-342 (2005).
27. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Stahl, S., and Frejd, F. Y., Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett., 584, 2670-2680 (2010).
28. Lu, D., Wientjes, M. G., Lu, Z., and Au, J. L., Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther., 322, 80-88 (2007).
29. Lu, Y., Yang, J., and Sega, E., Issues related to targeted delivery of proteins and peptides. AAPS J., 8, 466-478 (2006).
30. Lu, Z., Yeh, T. K., Wang, J., Chen, L., Lyness, G., Xin, Y., Wientjes, M. G., Bergdall, V., Couto, G., Alvarez-Berger, F., Kosarek, C. E., and Au, J. L., Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J. Urol., 185, 1478-1483 (2011).
31. Luo, F. R., Yang, Z., Dong, H., Camuso, A., Mcglinchey, K., Fager, K., Flefleh, C., Kan, D., Inigo, I., Castaneda, S., Wong, T. W., Kramer, R. A., et al., Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin. Cancer Res., 11, 5558-5565 (2005).
32. Mastrobattista, E., Crommelin, D. J., Wilschut, J., and Storm, G., Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J. Liposome Res., 12, 57-65 (2002).
33. Minchinton, A. I. and Tannock, I. F., Drug penetration in solid tumours. Nat. Rev. Cancer, 6, 583-592 (2006).
34. Na, S. J., Chae, S. Y., Lee, S., Park, K., Kim, K., Park, J. H., Kwon, I. C., Jeong, S. Y., and Lee, K. C., Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. Int. J. Pharm., 363, 149-154 (2008).
35. Oh, J. M., Ryu, Y. K., Lim, J. S., and Moon, E. Y., Hypoxia induces paclitaxel-resistance through ROS production. Biomol. Ther., 18, 145-151 (2010).
36. Park, K., Lee, G. Y., Kim, Y. S., Yu, M., Park, R. W., Kim, I. S., Kim, S. Y., and Byun, Y., Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J. Control. Release, 114, 300-306 (2006).
37. Park, K. M., Lee, S. Y., Joung, Y. K., Na, J. S., Lee, M. C., and Park, K. D., Thermosensitive chitosan-Pluronic hydrogel as an injectable cell delivery carrier for cartilage regeneration. Acta Biomater., 5, 1956-1965 (2009).
38. Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., and Tannock, I. F., The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res., 11, 8782-8788 (2005).
39. Torchilin, V. P. and Lukyanov, A. N., Peptide and protein drug delivery to and into tumors: Challenges and solutions. Drug Discov. Today, 8, 256-299 (2003).
40. Trabzuni, D., Famulski, K. S., and Ahmad, M., Functional analysis of tumour necrosis factor-alpha-related apoptosisinducing ligand (TRAIL): Cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem. J., 350 Pt 2, 505-510 (2000).
41. Tredan, O., Galmarini, C. M., Patel, K., and Tannock, I. F., Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst., 99, 1441-1454 (2007).
42. Verel, I., Heider, K. H., Siegmund, M., Ostermann, E., Patzelt, E., Sproll, M., Snow, G. B., Adolf, G. R., and Van Dongen, G. A., Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44v6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer, 99, 396-402 (2002).
43. Vinogradov, S. V., Bronich, T. K., and Kabanov, A. V., Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Adv. Drug Deliv. Rev., 54, 135-147 (2002).
44. Weiner, L. M., Surana, R., and Wang, S., Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 10, 317-327 (2010).
45. Wild, R., Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther., 5, 104-113 (2006).
46. Wong, H. L., Shen, Z., Lu, Z., Wientjes, M. G., and Au, J. L., Paclitaxel tumor-priming enhances sirna delivery and transfection in 3-dimensional tumor cultures. Mol. Pharm., 8, 833-840 (2011).
47. Yan, L., Hsu, K., and Beckman, R. A., Antibody-based therapy for solid tumors. Cancer, 14, 178-183 (2008).
48. Yan, L., Ehrlich, P. J., Gibson, R., Pickett, C., and Beckman, R. A., How can we improve antibody-based cancer therapy? MAbs, 1, 67-70 (2009).
49. Youn, Y. S., Shin, M. J., Chae, S. Y., Jin, C.-H., Kim, T. H., and Lee, K. C., Biological and physicochemical evaluation of the conformational stability of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). Biotechnol. Lett., 29, 713-721 (2007).